A systematic literature review of real-world treatment outcomes of small cell lung cancer

Michael Stokes, MPH\textsuperscript{a}, Noami Berfeld, MSc\textsuperscript{b}, Alicia Gayle, MSc\textsuperscript{c,*,} Andrew Descoteaux, MS\textsuperscript{a}, Oscar Rohrmoser, MD\textsuperscript{d}, April Franks, PhD\textsuperscript{d}

Abstract

Background: Robust evidence from real-world studies is needed to aid decision-makers and other stakeholders in choosing the best treatment options for patients. The objective of this work was to assess real-world outcomes of treatment strategies for limited- and extensive-stage small cell lung cancer (SCLC) prior to the global introduction of immunotherapies for this disease.

Methods: Searches were conducted in MEDLINE and Embase to identify articles published in English from October 1, 2015, through May 20, 2020. Searches were designed using a combination of Medical Subject Headings (Medline), Emtree (Embase subject headings), and free-text terms such as SCLC. Observational studies reporting data on outcomes of initial treatment strategies in patients with limited- and extensive-stage SCLC were included. Studies with limited sample sizes (<100 patients), enrolled all patients prior to 2010, or did not report outcomes for limited- and extensive-stage SCLC separately were excluded. Data were extracted into a predesigned template by a single researcher. All extractions were validated by a second researcher, with disagreements resolved via consensus.

Results: Forty articles were included in this review. Most enrolled patients from the United States (n = 18 articles) or China (n = 12 articles). Most examined limited-stage (n = 27 articles) SCLC. All studies examined overall survival as the primary outcome. Articles investigating limited-stage SCLC reported outcomes for surgery, chemotherapy and/or radiotherapy, and adjuvant prophylactic cranial irradiation. In studies examining multiple treatment strategies, chemoradiotherapy was the most commonly utilized therapy (56%–82%), with chemotherapy used in 18% to 44% of patients. Across studies, median overall survival was generally higher for chemoradiotherapy (15–45 months) compared with chemotherapy alone (6.0–15.6 months). Studies of extensive-stage SCLC primarily reported on chemotherapy alone, consolidative thoracic radiotherapy, and radiotherapy for patients presenting with brain metastases. Overall survival was generally lower for patients receiving chemotherapy alone (median: 6.4–16.5 months; 3 years, 5%–14.9%) compared with chemoradiotherapy in combination with consolidative thoracic radiotherapy (median: 12.1–18.0 months; 3 years, 15.0%–18.1%). Studies examining whole-brain radiotherapy for brain metastases reported lower median overall survival (5.6–8.7 months) compared with stereotactic radiosurgery (10.0–14.5 months).

Conclusions: Under current standard of care, which has remained relatively unchanged over the past few decades, prognosis remains poor for patients with SCLC.

Abbreviations: BID = twice daily, BM = brain metastases, CRT = chemoradiotherapy, CT = chemotherapy, HR = hazard ratio, IST = interval of simultaneous treatment, NCCN = National Comprehensive Cancer Network, NCDB = National Cancer Database, NR = not reached, OS = overall survival, PCI = prophylactic cranial irradiation, PET = positron emission tomography, PR = partial response, PSM = propensity score matching, QD = once daily, RCT = randomized controlled trial, RT = radiotherapy, RW = real world, SCLC = small cell lung cancer, SLR = systematic literature review, SOC = standard of care, SRS = stereotactic radiosurgery, TNM = tumor, lymph nodes, metastases, TRT = thoracic radiotherapy, US = United States, WBRT = whole-brain radiotherapy.

Keywords: epidemiology, outcomes, overall survival, small cell lung cancer, treatment patterns

This study was funded by AstraZeneca.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Michael Stokes is a full-time employee of Evidera, holds PPD stock options, and received funding from AstraZeneca. Noami Berfeld and Andrew Descoteaux are full-time employees of Evidera and received funding from AstraZeneca. Alicia Gayle, Oscar Rohrmoser, and April Franks are full-time employees of AstraZeneca and hold AstraZeneca stocks options. Supplemental Digital Content is available for this article.

*Correspondence: Alicia Gayle, Epidemiology, AstraZeneca, OBU, Global Medical Affairs, Global Real World Evidence Generation, City House, 126–130 Hills Road, Cambridge CB2 1RY, United Kingdom (e-mail: alicia.gayle@astrazeneca.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Stokes M, Berfeld N, Gayle A, Descoteaux A, Rohrmoser O, Franks A. A systematic literature review of real-world treatment outcomes of small cell lung cancer. Medicine 2022;101:26(e29783).

Received: 9 June 2021 / Received in final form: 24 November 2021 / Accepted: 25 May 2022

http://dx.doi.org/10.1097/MD.0000000000029783
1. Introduction

Worldwide, there are >1,800,000 new cases of lung cancer each year.[1] Approximately 15% of new lung cancer cases are small cell lung cancer (SCLC),[2] which is characterized by late diagnosis, poor prognosis, and high frequency of recurrence with existing treatments.[3-5] Lung cancer primarily affects older adults, with a median age at diagnosis of 71 years.[6] Men and women are affected, though incidence rates are higher for men.[7] Based on the National Cancer Institute Surveillance, Epidemiology, and End Results Program data for SCLC in 2017, men and women had age-adjusted incidences of 5.87 and 5.30 cases per 100,000 individuals, respectively.[8,9]

There are many prognostic factors to consider for SCLC, including age, presence of metastasis, and performance status.[10] Lung cancer is mainly caused by smoking. For SCLC, the risk is highly elevated for current smokers (odds ratio >100).[10]

The Veterans Administration Lung Study Group 2-stage system is typically used to classify SCLC into limited- and extensive-stage diseases. Limited stage refers to cancer that is confined to only 1 lung that can be treated within a single radiation field; extensive stage describes cancer that has spread throughout the lungs or to other organs.[11] The American Joint Committee on Cancer tumor, lymph nodes, metastases (TNM) system, which categorizes disease into stages I to IV,[12,13] is also used. Typically, TNM stage I to III and stage IV map to limited and extensive stages, respectively. Most patients (two-thirds) present with extensive-stage disease, where treatment options are poor and vary depending on disease stage at presentation.

Patients with limited-stage disease are often treated with chemoradiotherapy (CRT) and surgery or radiation for stages I to IIA; chemotherapy (CT) alone has been the standard of care (SOC) in the treatment of extensive-stage disease for the last several decades.[14] According to National Comprehensive Cancer Network (NCCN) guidelines, the preferred primary systemic therapy regimen for limited-stage SCLC includes a platinum agent (such as cisplatin) in combination with etoposide[15]; this has been the SOC for >30 years.

For extensive stage, randomized clinical trials (RCTs) recently demonstrated survival benefits with the addition of immunotherapy to CT. In the phase III CASPIAN trial, durvalumab plus platinum-etoposide was associated with a significant improvement in median overall survival (OS; 13.0 vs 10.3 months) over platinum-etoposide alone (hazard ratio [HR] = 0.73; P = .0047).[16] Additionally, in the phase III IMPower133 trial, atezolizumab with carboplatin–etoposide showed significant improvement in median OS (12.3 vs 10.3 months; HR = 0.70; P = .007) and progression-free survival (5.2 vs 4.3 months; HR = 0.77; P = .02) compared with placebo with carboplatin–etoposide.[17] The NCCN guidelines now recommend combining durvalumab or atezolizumab with platinum-based CT as first-line treatment for extensive-stage SCLC.[9]

While the efficacy of immunotherapy has been studied in RCTs, data on their real-world (RW) effectiveness in SCLC is limited. To aid decision-makers and other stakeholders in choosing the best treatment options for patients, robust evidence from RW studies is needed. The aim of our review was to provide an overview of RW outcomes, particularly OS, of initial treatment strategies for limited- and extensive-stage SCLC reported in studies published between October 1, 2015, to May 20, 2020.

2. Methods

We considered recommendations from the Cochrane Collaboration[18] and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines[19] in the design, conduct, and reporting of the systematic review. Given the nature of this work, specific ethics/institutional review board approval was not applicable.

2.1. Search strategies

Searches were conducted to identify RW observational studies examining: (1) the prevalence and incidence of SCLC or (2) treatment patterns and associated outcomes in patients with limited-stage and extensive-stage SCLC. Searches were conducted in MEDLINE (via PubMed.com) and Embase (via Embase.com) to identify original articles published in English from October 1, 2015, to May 20, 2020. This period was chosen to focus on recently published data, consistent with the study’s aim to collect outcomes data from contemporary samples of patients to increase the usability of the data. The studies published prior to October 1, 2015, would have likely included the majority of patients using an enrollment end date that was several years prior to 2015. The searches were conducted on May 20, 2020, and were designed using a combination of Medical Subject Heading (Medline), Emtree (Embase subject headings), and free-text terms included in the abstract or title of a publication. The detailed search strings and corresponding numbers of identified publications are provided in Supplementary Tables 1 and 2, http://links.lww.com/MD/G814.

2.2. Study selection

The publications identified by the database searches were deduplicated and screened against predefined inclusion and exclusion criteria (Supplementary Table 3, http://links.lww.com/MD/G814). Studies were included if they reported data on patients with SCLC and assessed disease incidence or prevalence or examined outcomes (including mortality, OS, disease progression, or progression-free survival). Studies were excluded if they had limited sample sizes (<100 patients), enrolled all patients prior to 2010, or did not report OS or progression outcomes, separately, for limited and/or extensive stages. Only full-text papers published in English were included.

Level 1 abstract screening was conducted by 1 researcher with an initial 15% random sample screened by a second researcher. Upon validation of this initial sample, the accuracy of the included abstracts was deemed acceptable, and no further validation was conducted. Insufficient information in the abstract was not a criterion for exclusion. The full-text articles were retrieved for all abstracts passing the first round of review. Full-text (level II) screening was conducted independently by 2 reviewers. Any discrepancies in decisions to include/exclude studies were resolved by consensus, with input from a third researcher when necessary. For this review, only a subset of studies comparing outcomes of initial treatment strategies was included. Additionally, limited SCLC studies reporting results for TNM stage subgroups only (e.g., stage I or stage III only) were excluded.

2.3. Data extraction and synthesis

Data on median OS (months), OS rates at 1, 3, and 5 years, initial treatment strategy, SCLC stage, and data source type were extracted for this study into a predesigned template by a single researcher. All extractions were validated by reviewers with disagreements resolved via consensus. Extracted data were grouped according to SCLC stage (limited vs extensive) and synthesized qualitatively. Median estimates (and ranges) for OS statistics were summarized across all included studies by SCLC stage and treatment strategy. Study characteristics, including whether the sample size was ≥500, use of statistical analyses to adjust for confounding effects, and if the study included data on baseline performance status, were also extracted for a simple assessment of study quality. Studies without these characteristics were deemed to be of lower quality compared to studies with some or all of these traits. Note: all included studies used clinical data such as physician diagnoses recorded on medical charts...
to identify patients with SCLC and classify them by limited and extensive stages.

3. Results

3.1. Search results

Database searches identified 1298 unique publications, of which 40 fulfilled the study selection criteria (Fig. 1). Twenty-five publications reported outcomes data for limited stage, 13 for extensive stage, and 2 for both. All studies examined OS as the primary outcome. Studies from China (limited n = 10 extensive n = 6) and the United States (US) (limited n = 12 extensive n = 6) comprised the majority of studies included in the review. Collectively, the studies examining limited- and extensive-stage SCLC enrolled 109,841 and 37,094 patients, respectively.

3.2. Study characteristics and quality assessment

3.2.1. Limited stage.

Among the studies examining outcomes of limited-stage SCLC, approximately one-third enrolled patients from large, population-based data sources with a sample size of n ≥ 500. Studies examined patients residing in the US using the secondary National Cancer Database (NCDB) or Surveillance, Epidemiology, and End Results, with 1 examining patients identified from a cancer registry in the Netherlands. The NCDB captures data for 70% of new cancer diagnoses from >1500 Commission on Cancer-accredited program registries in the US. Most studies identified enrolled patients with limited-stage SCLC from single centers with n < 500 patients.

Figure 1. Flow diagram of study selection process. Combined hits from searches described in Supplementary Tables 1 to 2, http://links.lww.com/MD/G814.

| Identification | Abstract records excluded N=998 |
|----------------|---------------------------------|
| Hits from database searches N=1,650 | • Conference abstracts/hone available = 16 |
| Abstract screening N=1,289 | • Insufficient data = 47 |
| Full-text eligibility N=291 | • Animal, in vitro, genetic or pharmacokinetic/dynamic studies, case reports, SLR/meta-analyses, narrative/expert reviews, letters = 225 |
| Relevant articles N=107 | • No articles with limited sample sizes (<100) = 97 |
| Articles included N=40 | • Not outcomes of interest = 484 |
| Limited-stage SCLC = 25 | • Not SCLC-specific = 107 |
| Extensive-stage SCLC = 13 | • RCT = 9 |
| Both stages = 2 | |

Articles excluded from review (N=67) reporting on:
- Incidence of SCLC = 11
- Outcomes associated with biomarkers = 13
- Outcomes associated with other factors = 18
- Outcomes reported only for limited-stage TNM subgroups (e.g., stage I) or limited-stage studies involving single treatment arms only = 23
- Treatment outcomes for relapse/progression = 2
Ten studies were identified that compared initial treatment with surgery (± other treatment strategies) to nonsurgical modalities.\cite{25,32–36,38–40,56} Prophylactic cranial irradiation (PCI; yes vs no) was examined in 10 studies; of which 3 looked at PCI following surgery\cite{17,41,53} and 7 examined PCI following CT or CRT.\cite{19,20,22,24,27,41,53} Four studies compared various nonsurgical treatment strategies, including CRT versus CT alone,\cite{17,20,22,24} CRT vs radiotherapy (RT) alone,\cite{21,22} and CRT vs palliative CT or RT.\cite{19,25} Five studies examined various aspects of treatment with CRT, including CRT with radiation delivered twice daily (BID) vs radiation delivered once daily (QD),\cite{18,22,24} and concurrent vs sequential CRT.\cite{18,23,24}

Nearly all studies examining limited-stage SCLC employed statistical methods to adjust for differences in baseline characteristics (e.g., age, sex, and stage) between study groups when examining OS. The most commonly used statistical methods included Cox proportional hazard models.\cite{17–19,22,24,25–28,30,31,33–36,38,39,41,55,56} Matching with propensity scores\cite{17,29,31,35,57} or alternate methods\cite{42–44,54,56} were used in 6 publications. Five studies did not use any statistical adjustment of outcomes,\cite{20–22,24,40} of which only 2 reported that groups were balanced with respect to baseline characteristics.\cite{21,40} Although all studies included cancer stage as a baseline variable, approximately one-half reported data on performance status,\cite{19–22,24,26,29,31,32,37,41,55,56} an important covariate that can influence prognosis. Therefore, residual confounding was likely an issue in many studies.

### 3.2.2. Extensive stage

Most publications examining patients with extensive-stage SCLC had <500 patients,\cite{42–44,46–48,53–56} with enrollment at single study sites. Of these, most examined patients in China,\cite{44,46–48,53–56} with 2 studies enrolling patients in the US,\cite{28,29} and another in Germany.\cite{19} Only one-quarter of studies included data from population-based sources and had a sample n ≥ 500.\cite{44,45,50,52} Among these, all used data from the US NCDB.

Consolidative thoracic radiotherapy (RT) following CT was compared with CT alone in 7 studies.\cite{42,46,47,52–54,56} PCI was examined in 3 studies,\cite{44,51,53} with 2 comparing PCI versus no PCI,\cite{43,51} following CT. Three studies compared whole-brain radiotherapy (WBRT) with stereotactic radiosurgery (SRS) in patients with brain metastases (BM).\cite{44,45,50} One study compared WBRT versus CT alone\cite{44} and another compared outcomes after WBRT in groups with synchronous versus metachronous BM.\cite{43}

Statistical analyses adjusting for patient characteristics were used in every study comparing treatment strategies, with most using propensity score matching (PSM) and Cox proportional hazards models.\cite{45–52} 5 employed Cox proportional hazard models only\cite{42–44,54,56} and 1 used PSM only.\cite{53} One study was noncomparative and followed patients after PCI only.\cite{53} Most (two-thirds) studies reported data on performance status\cite{42–44,46–48,53–56} and, of these, nearly all enrolled patients outside the US. No publications using the US NCDB included performance status, raising questions as to how well these studies could adequately control for confounding.

### 3.3. Outcomes of limited-stage SCLC

OS according to treatment strategy for limited-stage SCLC is shown in Table 1 and Supplementary Table 4, http://links.lww.com/MD/G814. The median OS exceeded 20 months (range: 18–79 months) in nearly every study examining treatment strategies that included surgery. The highest OS was found in a study of patients (n = 92) undergoing surgery and adjuvant CT with/without RT at West China Hospital.\cite{20} This study enrolled relatively young patients (72% <60 years old), and nearly two-thirds were nonsmokers.

There was general agreement across studies that surgery resulted in a significant OS benefit compared with receipt of nonsurgical modalities only. Only a small fraction of patients was eligible for surgery. Among the studies enrolling patients with stage I to III disease, the proportion undergoing surgery was 4.2% to 10.8%.\cite{42,43,38,39,56} An OS benefit favoring surgery

### Table 1

#### OS by treatment strategy: limited stage.

| Treatment strategy | Median OS (mo) | OS at 1 yr (%) | OS at 5 yr (%) | References |
|--------------------|----------------|----------------|----------------|------------|
| Surgery + CRT      | 25             | 86             | 40             | Wei, 2020\cite{39} |
| Surgery + RT ± CT  | 22–26         | 85.7 (78.3–92) | 43             | Kim, 2017\cite{41}, Jin, 2018\cite{42} |
| Surgery + CT       | 38.6 (18–79)  | 91 (70–100)    | 35.3 (28–45)   | Wei, 2020\cite{39}, Elegbede, 2020\cite{56}, Zhong, 2020\cite{40}, Takenaka (Japan)\cite{20} |
| Surgery without RT | 32 (26–37)    | 82 (75–87)     | 42 (39–45)     | Kim, 2017\cite{41}, Jin, 2018\cite{42}, Chen, 2019\cite{17} |
| Surgery + CT/RT    | 25.5 (20–31)  | 73.9 (67.8–80) | 34.0 (30–38)   | Yang, 2019\cite{42}, Wang, 2020\cite{42} |
| Surgery without RT| 23             | 59             | 30             | Che, 2018\cite{42} |
| CRT                | 21.5 (15–45)  | 69.3 (60–93)   | 19.6 (15–45)   | Wei, 2020\cite{39}, Elegbede, 2020\cite{56}, Chen, 2019\cite{17}, Zhong, 2020\cite{40}, (China)\cite{40}, Pezzi, 2018\cite{42}, Corso, 2015\cite{42}, Ohara, 2018\cite{42} |
| QD CRT             | 27.8 (26–29.5)| 90             | 20.7 (13.3–28.9)| Han, 2015\cite{40}, Danhuis, 2018 (the Netherlands)\cite{40} |
| BID CRT            | 29.2 (27–31.4)| 91             | 21.8 (19.6–22.9)| Han, 2015\cite{40}, Danhuis, 2018 (the Netherlands)\cite{40} |
| Sequential CRT     | 17.5 (17–41)  | 80 (80–80)     | 19 (16–42)     | Danhuis, 2018 (the Netherlands)\cite{40}, Manapov, 2016 (Germany)\cite{40}, Ohara, 2018\cite{40} |
| CT/RT              | 14 (11–24)    | 63 (50–75)     | 19 (10–26)     | Yang, 2019\cite{39}, Wang, 2020\cite{39}, Takenaka, 2015\cite{40}, Elegbede, 2020\cite{56}, Jin, 2018\cite{42} |
| CT alone           | 10.3 (6–15.6) | 37.5 (19–42)   | 8.1 (4–15.4)   | Wei, 2020\cite{39}, Pezzi, 2018\cite{42}, Corso, 2015\cite{42}, Ohara, 2018\cite{42} |
| Surgery + PCI      | 36 (26–38)    | 90 (84–95)     | 43 (40–59)     | Resio, 2019\cite{40}, Yin, 2018\cite{40}, Xu, 2017\cite{42} |
| Surgery without PCI| 30 (25–60)   | 82 (78–85)     | 33.8 (31–50)   | Resio, 2019\cite{40}, Yin, 2018\cite{40}, Xu, 2017\cite{42} |
| CRT + PCI          | 26 (24–39)    | 90 (80–96)     | 32 (15–38)     | Farooqi, 2017\cite{40}, Fairchild, 2020\cite{56}, Qiu, 2016\cite{40}, Lou, 2017\cite{40}, Koh, 2019\cite{40}, Choi, 2017\cite{40}, Eze, 2017\cite{40} |
| CRT§ (without PCI) | 18 (14–42)    | 82 (45–90)     | 19 (9–39)      | Farooqi, 2017\cite{40}, Qiu, 2016\cite{40}, Koh, 2019\cite{40}, Choi, 2017\cite{40}, Eze, 2017\cite{40} |

* Median estimate (range) for OS statistics across all included studies in category reported.
* = could not be calculated, BID = twice daily, CRT = chemoradiotherapy, CT = chemotherapy, NR = not reached, OS = overall survival, PCI = prophylactic cranial irradiation, QD = daily, RT = radiotherapy, yr = years.
† One-year survival rates not reported.
‡ Use of CRT ranged from 76% to 100%.
§ Use of CRT ranged from 76% to 100%.
comparing with treatment with CT and/or RT was observed in patients in stage I to II (median: 31–34 vs 23–24 months, \( P < .001 \)).\(^{18,23}\) Stage I to III (26 not reached vs 6 months, \( P < .001 \)).\(^{18,23}\) and stage IIIB-IIIC SCLC (20 vs 14 months, \( P < .001 \)).\(^{18,23}\) as well as in patients in stage (III–II) with no evidence of receipt of CT (\( P < .001 \)).\(^{18,23}\) Surgery with CT/CRT conferred a significant survival advantage compared with CT/CRT alone (median OS: 18–79 vs 12–23 months, \( P < .05 \)).\(^{20,46,16}\) and relative to palliative CT or RT (40.2 vs 10.7 months, \( P < .001 \)).\(^{18,23}\) in stage I to II SCLC. Surgery did not result in a significant survival advantage in patients with stage II to III SCLC\(^{18,23}\) or in subgroups with stage IIIB or IIIC.\(^{18,23}\)

The studies examining patients who did not undergo surgery tended to report higher OS among patients treated with CRT (range: 15–45 months) compared with groups receiving CT and/or RT (11–24 months) and CT alone (6–15.6 months) (Table 1). In studies enrolling patients across multiple treatment strategies, CRT was the most commonly utilized therapy (56%–82%); CT was used in 18% to 44% of patients and RT only in 2% to 4% (Fig. 2A). Four studies compared outcomes of CRT directly with treatment strategies other than surgery\(^{17,24,25,56}\) (Fig. 3). Significant OS benefits were achieved for patients receiving CRT relative to CT alone (median: 15–32.0 vs 7.5–10.5 months, \( P < .001 \)).\(^{17,24,25,56}\) RT alone (8.3 months, \( P < .001 \)).\(^{18,23}\) and CRT compared with palliative CT or RT (32 vs 10.7 months, \( P < .001 \)).\(^{18,23}\) There was significant variability in OS estimates across the studies examining CRT. OS was lowest in groups receiving sequential CRT\(^{18,23}\) (and in a study enrolling only elderly patients (≥70 years old)).\(^{18,23}\) The highest OS was found in a study enrolling younger patients (64% < 60 years old) with high-performance status (93% Karnofsky Performance Status ≥90).\(^{18,23}\)

Several studies examined whether BID RT with CT had a survival benefit over QD administration\(^{18,21,28}\) (Fig. 3). Only Schreiber et al\(^{18}\) reported a statistically significant OS benefit favoring BID administration (median: 22.1 vs 18 months, \( P < .001 \)). However, results should be viewed with caution as the authors did not have access to key variables such as performance status. It is possible that those with worse status were more likely to undergo QD radiation due to better tolerability compared with BID regimens.

Three studies examined the timing of radiation therapy\(^{18,23,24}\) relative to CT (Fig. 3). Damhuis et al\(^{18}\) reported a statistically significant OS benefit favoring concurrent CRT versus sequential CRT (median: 26–27 vs 17 months, \( P < .001 \), all) and Ohara et al\(^{18,23}\) did not. Ohara et al did not perform any statistical adjustment to account for differences in baseline characteristics. Additionally, there were notable differences in the age of the cohorts in Ohara et al. For example, patients in the sequential group were much younger compared with the concurrent group. Manapov et al\(^{18}\) examined CRT and the impact of interval of simultaneous treatment (IST) durations, where IST was defined as the interval in days where CT and RT were applied simultaneously. Although, the sequential (IST = 0) treatment group (median OS: 17.5 months) had significantly lower survival compared with IST > 0 to < 35 (38.4 months) (\( P < .05 \)), when the IST exceeded 35 days (16 months), no benefit over sequential CRT was realized.

Ten studies examined the benefits of PCI following initial treatment. Median OS ranged from 24 months to not reached (59% survival at 5-year follow-up) in patients receiving PCI. OS was heavily influenced by initial treatment type. In groups receiving surgery\(^{17,30,31,58}\) 5-year OS rates ranged from 40% to 59% compared with 15% to 38% in patients initially treated with CT or CRT\(^{19,20,22,26,37,41,53}\) (Table 1). Among the studies of PCI following surgery, a statistically significant OS benefit favoring PCI was observed in stage II (median: 36.4 vs 24.1 months, \( P = .047 \)), stage (median: 29.3 vs 21.2 months, \( P = .009 \)).\(^{18,23}\) Stage IIIA (5-year rate: 35.9% vs 18.8%, \( P = .047 \)).\(^{30}\) and node positive (35% vs 20%, \( P = .008 \)).\(^{56}\) SCLC, but not in node negative\(^{27}\) or stage IIIB SCLC. In the studies comparing PCI with no PCI in patients treated with CRT or CT, there was broad agreement that PCI results in a significant OS benefit\(^{19,20,22,26}\) (Fig. 3). One exception was in Choi et al\(^{41}\) which examined the effect of more accurate staging with positron emission tomography (PET) on the role of PCI. The authors noted that patients who had initial staging with PET achieved long-term survival even without PCI.

### 3.4. Outcomes of extensive-stage SCLC

OS according to treatment strategy for extensive-stage SCLC is summarized in Table 2 and Supplementary Table 5, http://links.lww.com/MD/G814. The median OS for patients treated with CT alone\(^{12,42,44,46,47,49,51–54,56}\) ranged from 6.4 to 16.5 months, with median OS exceeding 1 year in only 2 studies\(^{12,44}\). In these 2 studies, nearly all (91%)\(^{12}\) or all patients\(^{44}\) receiving platinum-based CT responded to treatment. The lowest OS was observed in a study enrolling patients ≥75 years old with BM (n = 238) from the NCDB.\(^{12}\) Studies that primarily enrolled patients with 1 metastatic site\(^{12}\) and those that excluded patients with disease progression\(^{47}\) or nonresponse to CT\(^{44}\) tended to report higher OS compared with studies enrolling primarily patients with polymetastases\(^{53}\) or BM\(^{49}\) studies.

![Figure 2. Use of treatment strategies for (A) limited-stage SCLC and (B) extensive-stage SCLC. *Study was limited to patients undergoing chemotherapy. Other category includes: *no chemo or radiotherapy; †surgery only; *not reported in article; ‡chemotherapy (without consolidative TRT); #chemotherapy (without PCI); ‡enrollment from single study center. Note: [x], reference number; studies enrolling patients across multiple treatment strategies depicted in figure. CRT = chemoradiotherapy, CT = chemotherapy, PCI = prophylactic cranial irradiation, RT = radiotherapy, TRT = thoracic radiotherapy, US = United States.](image-url)
without criteria requiring response to CT\cite{46,52}. In the publications reporting on CT regimens\cite{42,44,46,47,51,53,54,56}, nearly all patients (84%–100%) received platinum-based therapy. In the studies (3 from China and 1 from the US) reporting receipt of specific agents, 86% to 100% of patients enrolled received cisplatin-etoposide or carboplatin-etoposide regimens; 3 publications did not report information on the specific CT regimen received\cite{49,51,52}. Median OS for patients receiving CT and consolidative TRT (range: 12.1–18.0 months)\cite{42,46,47,52–54,56} or CT and PCI (range: 12.0–16.5 months)\cite{42,44,51,55} was ≥12 months (Table 2).

There was general agreement across studies showing that consolidative TRT following CT resulted in superior OS outcomes compared with CT alone\cite{42,47,52,53} (Fig. 4). However, Zhang et al\cite{54} found a significant benefit only for patients with oligometastases (median OS: 19.2 vs 15.6 months, \(P = .039\)), but not for those with brain/liver/multimetastasis. This contrasts with results from Xu et al\cite{55} which demonstrated a significant benefit in separate subgroups with oligometastases (2-year OS: 52.5% vs 12.7%, \(P = .002\)) and polymetastases (10.0% vs 6.8%, \(P = .030\)). Two studies enrolling patients without BM concluded that PCI following CT was beneficial compared with CT alone. In a study using the NCDB that excluded patients with OS <6 months as a proxy for lack of response to CT, median OS was 13.9 months for PCI versus 11.1 months for those who did not receive PCI (\(P < .001\))\cite{51}. Similarly, in a single-center study enrolling patients who had an initial response to CT, PCI significantly prolonged median OS from 12.6 to 16.5 months (\(P = .033\))\cite{44}. Another single-center study did not find a significant benefit favoring PCI\cite{42}. However, this study enrolled only patients ≥65 years old and failed to exclude those with BM. Data from large US population-based studies indicated that only 16.3% and 11.1% of patients receive TRT and PCI, respectively (Fig. 2B)\cite{51,52}. Although, in single-center studies, TRT treatment rates were much higher (34.4%–80.6%).

### Table 2

**OS by treatment strategy: extensive stage.**

| Treatment strategy          | Median OS (mo) | OS at 1 yr (%) | OS at 3 yr (%) |
|-----------------------------|----------------|----------------|----------------|
| CT alone                    | 11.1 (6.4–16.5)| 44 (15–65)     | 10 (6–14.9)    |
| CT + consolidative TRT      | 17.7 (12.1–18)| 65 (50.5–80)   | 15 (15–18.1)   |
| CT + PCI                    | 13.9 (12–16.5)| 64.0 (42–70)   | 13.8 (0–18.1)  |
| WBRT*                       | 7.1 (5.6–8.7) | 30 (18–41)     | 4 (4–16)       |
| WBRT + boost*               | 13.6 (9.3–17.9)| 53.5 (39–68) | 16.5 (6–27)    |
| SRS*                        | 12.9 (10–14.5)| 49 (42–54)     | 19 (7–31)      |

Median estimate (range) across included studies reported.

CT = chemotherapy, PCI = prophylactic cranial irradiation, SRS = stereotactic radiosurgery, TRT = thoracic radiotherapy, WBRT = whole-brain radiotherapy, yr = years.

* Treatment given to patients with brain metastases.

**Figure 3.** Median OS (months) of limited-stage SCLC nonsurgical treatment strategies. Note: [xx], reference number. BID = twice daily, CR = complete response, CRT = chemoradiotherapy, CT = chemotherapy, IST = interval of simultaneous treatment, PCI = prophylactic cranial irradiation, PET = positron emission tomography, PR = partial response, QD = daily, RT = radiotherapy.
In studies examining patients presenting with BM, median OS was consistently higher with SRS (range: 10.0–14.5 months) compared with WBRT (5.6–8.7 months) (Table 2). Three studies compared WBRT to SRS, 2 of which also assessed WBRT and boost (Fig. 4). A significant survival benefit for SRS compared with WBRT was observed in 2 studies using the NCDB; 1 enrolling patients from 2010 to 2014 (median OS: 10.8 vs 7.1 months, \( P < .001 \)) and the other from 2004 to 2013 (10.0 vs 8.2 months, \( P < .001 \)) [50]. Jiang et al [45] reported that SRS led to significantly better survival compared with WBRT and boost (10.0 vs 9.3 months, \( P < .001 \)). Ni et al [48], however, found that WBRT and boost significantly improved OS relative to SRS in the PSM analysis (21.8 vs 12.9 months, \( P = .040 \)), but not in the overall sample. One study found that WBRT led to a modest increase in survival (1.9 vs 1.2 months, \( P < .0001 \)) compared with no WBRT in the subgroup not treated with CT.

4. Discussion

This review provides insights into RW treatment patterns and outcomes for patients with limited- or extensive-stage SCLC. Despite the limitations associated with RW data, many studies comparing treatment strategies generated evidence consistent with findings from RCTs and treatment guidelines. To our knowledge, this is one of the first reviews in SCLC summarizing the RW evidence separately for limited and extensive stages.

4.1. Limited stage

NCCN guidelines recommend surgical resection with lobectomy as the preferred radical therapy in T1-2N0 SCLC only [9] which represents a small proportion of patients with SCLC. Consistent with this recommendation, we found that the surgery is infrequent in limited-stage SCLC (4.2%–10.8%). In recent years, investigators have shown that a multimodality approach including surgery may have benefits, particularly for stage I (cancer confined to 1 lung only) and II (cancer confined to 1 lung and nearby lymph nodes) patients, despite a lack of evidence from RCTs [59–61]. We identified 10 publications comparing multimodal therapy, including surgery to approaches using CT and/or RT only in limited-stage SCLC. Nearly all studies demonstrated significant survival benefits favoring treatment approaches including surgery; however, no improvement in OS following surgery was seen in patients with stage II–III SCLC.

For patients receiving CRT, median OS ranged from 15 to 45 months. Publications examining treatment with CT and/or RT (11–24 months) or CT alone (6–16 months) reported lower median OS relative to CRT. Concurrent CRT is the current SOC for limited-stage SCLC. Data from clinical trials found that concurrent CRT, where RT starts within the first or second cycle of CT, is more effective compared with sequential CRT [62–64]. Our review identified several RW studies examining the sequence and timing of RT with mixed results. Two showed a significant OS benefit favoring concurrent versus sequential CRT [18,23], whereas the study by Ohara et al [24] did not. However, no statistical adjustment of outcomes was conducted in Ohara et al, despite notable differences between groups in patient characteristics.

BM commonly occurs in patients with SCLC. More than 50% will develop BM within 2 years [65]. Therefore, PCI is considered the SOC in patients with limited-stage SCLC. PCI was associated with longer OS in nearly all studies identified examining PCI following surgery. However, a survival benefit was not observed in subgroups with node negative or stage I SCLC. In the studies of patients comparing PCI with no PCI following CT or CRT [19,20,22,26] all except Choi et al [41] observed a significant OS benefit for PCI. The authors noted that patients with an initial PET staging evaluation achieved long-term survival even without PCI.
4.2. Extensive stage

Consistent with treatment guidelines, most extensive-stage patients included in this review received CT only. Most studies reported a median OS ≤12 months for patients treated with CT alone, indicating the poor prognosis of extensive-stage SCLC. The most common type of CT regimen was platinum-based, used in 84% to 100% of patients with extensive-stage disease, which aligns with the established SOC for the past several decades. Recently, atezolizumab and durvalumab have demonstrated improvement in survival when combined with platinum-based regimens for first-line treatment of extensive-stage SCLC. However, we did not identify any RW studies examining these novel immunotherapies, which is likely a reflection of the review’s study period and the fact that it usually takes several years before records of these treatments show up in retrospective databases and cancer registries.

Historically, RT was reserved for palliation in extensive-stage SCLC. The fact that many patients had recurrent or progressive intrathoracic disease led to clinical trial investigations and other observational studies examining the role of consolidative TRT in this population. In the first RCT examining consolidative TRT following CT, TRT led to significant OS improvements. This review identified 6 studies comparing CT with or without consolidative TRT. A statistically significant OS benefit favoring TRT was reported in nearly all studies. Consolidative TRT is recommended in patients with complete response or good response following CT. Three studies examining PCI in extensive-stage SCLC were identified that reported mixed results. Two studies showed a significant OS improvement with PCI, however, no OS benefit was observed with PCI in a study enrolling only elderly patients. Mixed results in RCTs examining PCI in extensive-stage SCLC have also been reported. An RCT conducted by the European Organization for Research and Treatment of Cancer found that PCI improved survival, while another from Japan found no improvement compared with routine surveillance magnetic resonance imaging and treatment of asymptomatic BM. According to the NCCN guidelines, PCI is not recommended in patients with poor performance status or impaired neurocognitive function.

NCCN guidelines state that WBRT should typically be used as treatment in patients who present with BM. Although WBRT is considered the SOC for BM, the optimal therapeutic approach remains controversial. Two studies included in our review found that SRS was associated with significantly longer survival compared with WBRT. Although the studies included in this review were observational and the data cannot be used to definitively conclude that survival would be improved with one approach over another, the data suggest that SRS may be appropriate and lead to favorable outcomes for certain patient subgroups. An RCT is being conducted to compare SRS to WBRT.

4.3. Limitations

The searches for this systematic review were conducted in MEDLINE and Embase. Therefore, any publications that were relevant but not included in these databases were not captured in our search. As for any review, the current study is limited by the available literature and the possibility of publication bias. The systematic literature review included studies from a relatively short period of only 4.5 years. However, the size of the literature on SCLC is very large and the time period was sufficiently long to identify multiple studies reporting outcomes for all the SOC treatment strategies across various geographic regions. In addition, the review period allowed for the identification of studies enrolling patients from more recent time periods increasing the usability of the data. Validation of level I abstract screening was only conducted for a random sample (15%) of abstracts, and some accuracy may have been compromised compared to double-screening. As a substantial proportion of the publications were retrospective chart reviews or secondary database analyses, the data from the studies also had important limitations. For example, many publications did not report information on performance status, an important variable affecting prognosis. Although many studies used statistical methods to control for imbalances in patient characteristics, residual confounding was likely an issue. Additionally, in cases where the survival data was extracted from a graph, the information is inherently less precise.

5. Conclusions

The RW evidence collected as part of this systematic review reveals a limited number of available SCLC treatment options. Overall, the recent RW evidence was in alignment with established treatment recommendations and clinical trial results for SCLC. In limited stage, higher OS rates may be achieved with treatment approaches including surgery (vs without), particularly for stage I SCLC and, in patients ineligible for surgery, concurrent CRT is preferable to sequential CRT and approaches using CT or RT alone. Additionally, PCI following CRT provides an OS benefit compared to CRT alone in limited stage. In extensive stage, consolidative TRT following CT results in higher OS compared to CT alone. Further study is needed to determine if PCI following CT prolongs survival in extensive stage and whether SRS is more effective compared to WBRT in patients who present with BM. Under the current SOC, which has remained relatively unchanged over the past few decades, prognosis remains dismal for many patients with SCLC. Recently approved immunotherapies may be the beginning of a new era where significant improvements in outcomes are observed. Our findings will enable healthcare decision-makers and other stakeholders to put RCT data on emerging therapies into context with RW outcomes achieved under the current SOC.

Acknowledgments

This study was funded by AstraZeneca. Copy-editing and medical writing support was provided by Michael Grossi, of Evidera. Lisa Mather, of Evidera, contributed to abstract/full-text screening and data extraction.

Author contributions

Conceptualization – MS, NB, AD.
Data curation – MS, NB, AD.
Formal analysis – MS, NB, AD.
Funding acquisition – OR, AF.
Investigation – MS, NB, AD.
Methodology – MS, NB, AD.
Project administration– MS, NB, AD.
Resources– MS, NB, AD.
Software– MS, NB, AD.
Supervision– MS, NB, AD, OR, AF, AG.
Validation– MS, NB, AD.
Visualization – MS, NB, AD.
Writing – original draft – MS, NB, AD.
Writing – review and editing – MS, NB, AD, OR, AF, AG.

References

[1] World Health Organization. Fact sheet: cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Published 2018. [access date September 1, 2020].
[2] Cancer.Net. Lung cancer – small cell: statistics. https://www.cancer.net/cancer-types/lung-cancer-small-cell/statistics. Published 2020. [access date September 1, 2020].
[3] Asai N, Ohkuni Y, Kaneko N, et al. Relapsed small cell lung cancer: treatment options and latest developments. Ther Adv Med Oncol. 2014;6:69–82.

[4] American Cancer Society. Small cell lung cancer stages. https://www.cancer.org/cancer/small-cell-lung-cancer/detection-diagnosis-staging/staging.html. Published 2017. [access date September 1, 2020].

[5] National Cancer Institute. Cancer stat facts: lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungbh.html. Published 2020. [access date December 1, 2020].

[6] American Cancer Society. Key statistics for lung cancer. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html. [access date December 1, 2020].

[7] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

[8] National Cancer Institute. SEER cancer statistics review, 1975-2017. https://seer.cancer.gov/csr/1975_2017/browse county.php?sectionSel=15&pageSel=sect_15_table_07. [access date December 1, 2020].

[9] National Comprehensive Cancer Network (NCCN). NCCN Guidelines. version 3. Small cell lung cancer. https://www.nccn.org/professionals/physician_gls/default.aspx. Published 2020. [access date December 1, 2020].

[10] Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2012;131:1210–9.

[11] Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer—what limits limited disease? Lung Cancer. 2002;37:271–6.

[12] American Joint Committee on Cancer. AJCC Cancer Staging Handbook. 7th ed. New York: Springer; 2010.

[13] Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–39.

[14] Heron L, Mansfield AS, Szczeniwa A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9.

[15] Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from: www.cochrane-handbook.org; 2008.

[16] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

[17] Corso CD, Rutter CE, Park HS, et al. Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer. J Clin Oncol. 2015;33:4290–4.

[18] Damhuis R, Widder J, Senan S. Population-based results of chemoradiotherapy schedule parameters and overall survival in a real-life LD SCLC patient cohort. J Cancer. 2016;7:2012–7.

[19] Koh M, Song SY, Jo JH, et al. The value of prophylactic cranial irradiation in limited-stage small cell lung cancer: should it always be recommended? Radiat Oncol J. 2019;37:156–65.

[20] Ohara S, Kanda S, Okuma H, et al. Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutions. Jpn J Clin Oncol. 2018;48:82–8.

[21] Pezzi TA, Schwartz DI, Mohamed ASR, et al. Barriers to combined-modality therapy for limited stage small cell lung cancer. JAMA Oncol. 2018;4:e174504.

[22] Qin G, Du X, Zhou X, et al. Prophylactic cranial irradiation in 399 patients with limited-stage small cell lung cancer. Oncol Lett. 2016;11:2654–60.

[23] Resio BJ, Hoag J, Chiu A, et al. Prophylactic cranial irradiation is associated with improved survival following resection for limited stage small cell lung cancer. J Thorac Dis. 2019;11:811–8.

[24] Schiebler D, Wong AT, Schwartz D, et al. Utilization of hyperfractionated radiation in small-cell lung cancer and its impact on survival. J Thorac Oncol. 2015;10:1770–5.

[25] Takenaka T, Takenoyama M, Inamasu E, et al. Role of surgical resection for patients with limited disease-small cell lung cancer. Lung Cancer. 2015;88:52–6.

[26] Xu J, Yang H, Fu X, et al. Prophylactic cranial irradiation for patients with surgically resected small cell lung cancer. J Thorac Oncol. 2017;12:347–53.

[27] Yin K, Song D, Zhang H, et al. Efficacy of surgery and prophylactic cranial irradiation in stage II and III small cell lung cancer. J Cancer. 2018;9:3500–6.

[28] Chen MY, Hu X, Bao Y, et al. Comparison of long term results between matched chemoradiotherapy and surgery for limited stage small cell lung cancer. Lung Cancer. 2019;11:9049–55.

[29] Kim SK, Manzerova J, Christos P, et al. Impact of radiation therapy in surgically resected limited-stage small cell lung carcinoma. Lung. 2017;195:341–6.

[30] Jin K, Zhang K, Zhou F, et al. Selection of candidates for surgery as local therapy among early-stage small cell lung cancer patients: a population-based analysis. Cancer Commun (Lond). 2018;38:5.

[31] Wang Y, Zheng Q, Jia B, et al. Effects of surgery on survival of early-stage patients with SCLC: propensity score analysis and nomogram construction in SEER database. Front Oncol. 2020;10:626.

[32] Yang Y, Yuan G, Zhan C, et al. Benefits of surgery in the multimodality treatment of stage IIIB-IIIC small cell lung cancer. J Cancer. 2019;10:5404–12.

[33] Lou G, Du X, Zhou X, et al. Risk factors associated with brain metastases in patients with limited-stage small-cell lung cancer after prophylactic cranial irradiation. Int J Clin Exp Med. 2017;10:5203–9.

[34] Che K, Shen H, Qu X, et al. Survival outcomes for patients with surgical and non-surgical treatments in stages I-III small-cell lung cancer. J Cancer. 2018;9:1421–9.

[35] Wei S, Wei B, Tian J, et al. Comparison of treatment strategies for patients with limited-stage small cell lung cancer who received chemotherapy. Transl Cancer Res. 2020;9:818–26.

[36] Zhong L, Suo J, Wang Y, et al. Prognosis of limited-stage small cell lung cancer with comprehensive treatment including radical resection. World J Surg Oncol. 2020;18:27.

[37] Choi M, Lee Y, Moon SH, et al. Effect of accurate staging using positron emission tomography on the outcomes of prophylactic cranial irradiation in patients with limited stage small-cell lung cancer. Clin Lung Cancer. 2017;18:777–84.

[38] An C, Jing W, Zhang Y, et al. Thoracic radiation therapy could give survival benefit to elderly patients with extensive-stage small-cell lung cancer. Future Oncol. 2017;13:1149–58.

[39] Bernhardt D, Adeberg S, Bozorgmehr F, et al. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. J Neurooncol. 2017;134:205–12.

[40] Chen Y, Li J, Hu Y, et al. Prophylactic cranial irradiation could improve overall survival in patients with extensive small cell lung cancer: a retrospective study. Strahlenther Onkol. 2016;192:905–12.

[41] Jiang W, Haque V, Verma V, et al. Stereotactic radiosurgery for brain metastases from newly diagnosed small cell lung cancer: practice patterns and outcomes. Acta Oncol. 2019;58:491–8.

[42] Li-Ming X, Zhao LJ, Simone CB 2nd, et al. Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer. Radiother Oncol. 2017;125:331–7.

[43] Luo J, Xu L, Zhao L, et al. Timing of thoracic radiotherapy in the treatment of extensive-stage small-cell lung cancer: important or not? Radiat Oncol. 2017;12:42.

[44] Ni M, Jiang A, Liu W, et al. Whole brain radiation therapy plus focal boost may be a suitable strategy for brain metastases in SCLC patients: a multi-center study. Radiat Oncol. 2020;5:70.

[45] Renz P, Hasan S, Wegner RE. Survival outcomes after whole brain radiotherapy for brain metastases in older adults with newly diagnosed metastatic small cell carcinoma: a national cancer database (NCDB) analysis. J Geriatr Oncol. 2019;10:560–6.

[46] Robin TP, Jones BL, Amini A, et al. Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer. Lung Cancer. 2018;120:88–90.
[51] Sharma S, McMillan MT, Doucette A, et al. Effect of prophylactic cranial irradiation on overall survival in metastatic small-cell lung cancer: a propensity score-matched analysis. Clin Lung Cancer. 2018;19:260–69.e3.

[52] Tian S, Zhang X, Jiang R, et al. Survival outcomes with thoracic radiotherapy in extensive-stage small-cell lung cancer: a propensity score-matched analysis of the national cancer database. Clin Lung Cancer. 2019;20:484–93.e6.

[53] Xu LM, Cheng C, Kang M, et al. Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. Sci Rep. 2017;7:9255.

[54] Zhang H, Deng L, Wang X, et al. Metastatic location of extensive stage small-cell lung cancer: implications for thoracic radiation. J Cancer Res Clin Oncol. 2019;145:2605–12.

[55] Fairchild A, Guest N, Letcher A, et al. Should stereotactic radiosurgery be considered for salvage of intracranial recurrence after prophylactic cranial irradiation or whole brain radiotherapy in small cell lung cancer? a population-based analysis and literature review. J Med Imaging Radiat Sci. 2020;51:75–87.e2.

[56] Elegbede AA, Gibson AJ, Fu H, et al. Real-world adherence to guideline-recommended treatment for small cell lung cancer. Am J Clin Oncol. 2020;43:236–42.

[57] Liu Y, Shan L, Shen J, et al. Choice of surgical procedure—lobectomy, segmentectomy, or wedge resection—for patients with stage T1-2N0M0 small cell lung cancer: a population-based study. Thorac Cancer. 2019;10:593–600.

[58] Lou Y, Zhong R, Xu J, et al. Does surgically resected small-cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation? Thorac Cancer. 2020;11:1259–44.

[59] Shields TW, Huggins GA Jr, Matthews MJ, et al. Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg. 1982;84:481–8.

[60] Shepherd FA, Ginsberg RJ, Evans WK, et al. Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer. J Thorac Cardiovasc Surg. 1983;86:498–506.

[61] Shah SS, Thompson J, Goldstraw P. Results of operation without adjuvant therapy in the treatment of small cell lung cancer. Ann Thorac Surg. 1992;54:498–501.

[62] Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan clinical oncology group study 9104. J Clin Oncol. 2002;20:3054–60.

[63] De Ruyscher D, Pijls-Johannesma M, Vansteenkiste J, et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol. 2006;17:543–52.

[64] Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22:4837–45.

[65] Manapov F, Kasmann L, Roengvoraphoj O, et al. Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes. Lung Cancer (Auckl). 2018;9:49–55.

[66] Fruh M, De Ruyscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:v199–105.

[67] Tjong MC, Mak DY, Shahi J, et al. Current management and progress in radiotherapy for small cell lung cancer. Front Oncol. 2020;10:1146.

[68] Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999;17:2092–9.

[69] Slotman B, Favre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.

[70] Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663–71.

[71] Ni M, Liu W, Jiang A, et al. Whole brain radiation therapy plus focal radiation boost may generate better survival benefit for brain metastases from non-small cell lung cancer. Front Oncol. 2020;10:576700.

[72] Bernhardt D, Hommertgen A, Schmitt D, et al. Whole brain radiation therapy alone versus radiosurgery for patients with 1-10 brain metastases from small cell lung cancer (ENCEPHALON Trial): study protocol for a randomized controlled trial. Trials. 2018;19:388.